Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) was the recipient of a significant increase in short interest in November. As of November 15th, there was short interest totalling 2,582,415 shares, an increase of 4.9% from the October 31st total of 2,461,720 shares. Based on an average daily trading volume, of 163,408 shares, the short-interest ratio is presently 15.8 days. Approximately 8.2% of the company’s shares are sold short.

A number of brokerages have weighed in on AST. ValuEngine cut shares of Asterias Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 4th. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Asterias Biotherapeutics in a research report on Monday, October 2nd. Finally, Zacks Investment Research raised shares of Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $3.75 price target on the stock in a research report on Tuesday, October 10th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. Asterias Biotherapeutics has an average rating of “Hold” and an average target price of $9.19.

Shares of Asterias Biotherapeutics (NYSEAMERICAN AST) opened at $2.45 on Thursday. Asterias Biotherapeutics has a 12 month low of $2.00 and a 12 month high of $5.00.

ILLEGAL ACTIVITY NOTICE: “Asterias Biotherapeutics Inc (AST) Short Interest Update” was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at

Asterias Biotherapeutics Company Profile

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with's FREE daily email newsletter.